Dihydroimidazopyrimidopyrimidinones and uses thereof
By designing 8,9-dihydroimidozolo[1,2-a]pyrimido[5,4-e]pyrimidine-5(6H)-ketone compounds with low hERG channel inhibitory activity as Wee1 kinase inhibitors, the off-target side effects of existing drugs in cancer treatment have been solved, achieving more efficient and safer cancer treatment.
CN122161828APending Publication Date: 2026-06-05IMPACT THERAPEUTICS (SHANGHAI) INC +1
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- IMPACT THERAPEUTICS (SHANGHAI) INC
- Filing Date
- 2024-11-01
- Publication Date
- 2026-06-05
Smart Images
Figure CN122161828A_ABST
Abstract
Provided are compounds of Formula I, or stereoisomers, tautomers, N-oxides, hydrates, solvates, isotopically labeled compounds, or pharmaceutically acceptable salts thereof, or mixtures thereof. Compounds of Formula I are inhibitors of Wee1 kinase. Thus, these compounds are useful in the treatment of diseases caused by abnormal Weel activity. (I).
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Vehicle composition containing 1-substituted azacycloheptan-2-ones
US3989816A
Vehicle composition containing 1-substituted azacyclopentan-2-ones
US4444762A
Dihydropyrazolopyrimidinone derivatives
WO2007126122A1
Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
WO2015092431A1
8,9-dihydroimidazole[1,2-a]pyrimido[5,4-e]pyrimidine-5(6H)-ketone compound
WO2018090939A1